FDA clears Focus Diagnostics's flu/RSV test kit
This article was originally published in Clinica
The US FDA has issued 510(k) clearance for the Simplexa Flu A/B & RSV test on the 3M Integrated Cycler. The Simplexa test, developed by Quest Diagnostics subsidiary Focus Diagnostics (Cypress, California), is designed to detect and discriminate between influenza A, influenza B and respiratory syncytial virus (RSV) infections. It is the first molecular test cleared by the FDA for detecting flu viruses and RSV that does not require confirmation of test results by other methods, such as culture. The test takes about an hour to complete, and delivers results in less than three hours. The new test is the second Simplexa RT-PCR molecular test to run on the 3M integrated Cycler as part of a distribution agreement between Focus and 3M. In May, the Simplexa Influenza A H1N1 (2009) test became the first to receive FDA clearance for the detection of the 2009 H1N1 flu virus (www.clinica.co.uk, 25 May 2010).
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.